Intuitive Surgical (ISRG) Balances Earnings Growth With Valuation and Legal Pressures

Intuitive Surgical, Inc. is drawing investor scrutiny as strong core business metrics clash with high valuation multiples and sector volatility. Analysis from Zacks highlights the medical device maker's robust financial trajectory, projecting its earnings per share to grow 25.8% this year, compared to an industry average projection of 12%. Furthermore, the company's cash flow rose 15.8% year over year, significantly outpacing the broader industry average of 0.9%.

Despite positive growth metrics, the equity fell 3.35% on November 10, underperforming its sector. Market observers attributed the decline to macroeconomic pressures, broader sector valuation compression, and institutional adjustments. Institutional desks are closely watching hospital capital spending, where elevated financing costs and tight administrative budgets could lengthen procurement cycles for surgical equipment. The stock closed recently at $460.56, right around a key weekly horizontal resistance level of $460.57.

Fundamental reports show that Intuitive Surgical generated $10.06B in annual revenue and $2.86B in net profit, maintaining a balance sheet with no outstanding debt. In its third quarter, overall revenue increased 22% year over year to $3.05 billion, bolstered by a 14% rise in da Vinci procedures and a 31% jump in Ion procedures. System adoption expanded as well, with third-quarter placements of the next-generation da Vinci 5 reaching 315 units compared to 240 units in the prior-year period.

However, bottom-line results faced pressure from a $450 million pretax charge to settle an antitrust class-action lawsuit concerning proprietary instruments and servicing agreements. The charge reduced third-quarter GAAP earnings per share to $1.49, down from $1.95 a year earlier, even as adjusted earnings per share rose to $3.00. The charge also compressed operating margins, highlighting persistent legal challenges.

Valuation remains a core concern, with the stock trading at a forward price-to-earnings ratio of 37.13, exceeding the industry average of 28.65 and peers such as Medtronic at 16.49 and Johnson & Johnson at 24.04. Additional headwinds include planned 3% to 5% price reductions on instruments and emerging competitive platforms, such as Johnson & Johnson's OTTAVA, which received FDA De Novo authorization in July 2026. Across the past month, multiple analysts have maintained a Buy rating on the company, posting an average price target of $486.97.